Cramer’s lightning round: Stay away from CoreCivic

Cramer’s lightning round: Stay away from CoreCivic


Loading chart…

CoreCivic Inc: “Let’s just stay away.”

Loading chart…

Inmode Ltd: “If you want med tech, you just want Edwards Lifesciences.”

Loading chart…

Western Midstream Partners LP: “This one’s got a great yield, really good story.”

Loading chart…

SGHC Limited: “They are doing well, and I don’t say that idly.”

Loading chart…

Enterprise Products Partners LP: “They are the best in what they do.”

Loading chart…

United States Steel Corp: “If you’re going to own a steel company, which I don’t honestly recommend right now, you’re going to own Nucor.”

Loading chart…

Teva Pharmaceutical Industries Ltd: “I would prefer to see you in something like a [Johnson & Johnson].”

Loading chart…

AST SpaceMobile Inc: “I do not know that company, but we will do homework on it.”

VIDEO5:3105:31

Cramer’s lightning round: Stay away from CoreCivic

Mad Money with Jim Cramer

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer Twitter – Facebook – Instagram

Questions, comments, suggestions for the “Mad Money” website? [email protected]





Source

Nike cuts 1,400 roles in second round of layoffs this year
Business

Nike cuts 1,400 roles in second round of layoffs this year

People walk past a Nike store in New York City, on April 2, 2025. Kylie Cooper | Reuters Nike announced a new round of layoffs on Thursday impacting approximately 1,400 roles across the organization, mostly concentrated in its technology department. In a note from COO Venkatesh Alagirisamy, the company said the layoffs were part of […]

Read More
Trump administration moves to reclassify cannabis in major shift that could expand research
Business

Trump administration moves to reclassify cannabis in major shift that could expand research

The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug’s medical uses. The change would not legalize the drug at the federal level, but shift cannabis from its current status as a Schedule I substance to Schedule III under the U.S. Drug Enforcement Administration’s controlled […]

Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Business

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]

Read More